Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585182 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
A Phase 4 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT00585182 is a Phase 4 study that has completed, run by University of Utah. The registered enrollment target is 28 participants.
The verdict
NCT00585182, a Phase 4 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients. Generally, these medications are given in a fixed dose that is the same for everyone. The appropriate dose of medication in patients with severe obesity is uncertain. There is some evidence that the use of standard fixed-doses in severely obese patients may not provide adequate protection against DVT. The purpose of this study is to evaluate a weight-based dose(0.5 milligrams per kilogram of body weight) of the commonly prescribed LMWH, enoxaparin in severely obese patients to determine if predictable levels of blood thinning can be achieved. We hypothesize that dosing enoxaparin 0.5mg/kg once daily in severely obese patients will lead to predictable blood levels.
Interventions
- DRUG Enoxaparin 0.5 mg/kg once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585182
The ClinicalTrials.gov registry entry for NCT00585182 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin 0.5 mg/kg once daily is the first listed.
NCT00585182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585182 about?
NCT00585182 is a clinical study titled "Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT". Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients. Generally, these medications are given in a fixed dose that is the same for ...
What is the current status of trial NCT00585182?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2007-01. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00585182?
The interventions under investigation include: Enoxaparin 0.5 mg/kg once daily (DRUG).
Who is sponsoring clinical trial NCT00585182?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.